Treatment Patterns With Targeted Therapies In Mrcc In Sweden - A Retrospective Analysis Of Data From National Registries

Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma

NCT00930345 ·Status: TERMINATED ·Phase: PHASE4

Study In Patients With Kidney Cancer Treated With Sutent

NCT00873210 ·Status: COMPLETED

Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib

NCT04076787 ·Status: COMPLETED

A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine.

NCT05745142 ·Status: COMPLETED

Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments

NCT04175262 ·Status: COMPLETED

Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma

NCT02848768 ·Status: COMPLETED

Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients

NCT01934452 ·Status: COMPLETED

Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC

NCT06860386 ·Status: SUSPENDED ·Phase: PHASE2

Phase II Study of Alternating Sunitinib and Temsirolimus

NCT01517243 ·Status: COMPLETED ·Phase: PHASE2

A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus

NCT01798446 ·Status: COMPLETED ·Phase: PHASE2

Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib

NCT03592199 ·Status: UNKNOWN ·Phase: PHASE2

Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC

NCT03075423 ·Status: COMPLETED ·Phase: PHASE2

Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma

NCT02071641 ·Status: TERMINATED ·Phase: PHASE2

Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma

NCT00130897 ·Status: APPROVED_FOR_MARKETING

A Retrospective Medical Record Review of First-Line Sunitinib Administration Schedules and Outcomes Among Patients With mRCC in Latin America (LA)

NCT04115189 ·Status: COMPLETED

Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving Sunitinib as First Line Therapy.

NCT03140176 ·Status: TERMINATED

Sutent Rechallenge In mRCC Patients

NCT01827254 ·Status: COMPLETED

The Vascular and Metabolic Effects of Sunitinib in Patients With Metastatic Renal Cell Carcinoma

NCT01227213 ·Status: COMPLETED

Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response

NCT00694096 ·Status: COMPLETED ·Phase: PHASE1

Real-world Treatment Patterns and Outcomes Among aRCC Patients on Cabozantinib or Axitinib in England

NCT04637204 ·Status: COMPLETED

Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)

NCT01122615 ·Status: COMPLETED ·Phase: PHASE1

Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (Pharmetrics)

NCT01381601 ·Status: COMPLETED

Study Of SU011248 (Sunitinib) Given In A Continuous Daily Regimen In Patients With Advanced Renal Cell Cancer

NCT00137423 ·Status: COMPLETED ·Phase: PHASE2

Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer

NCT01064310 ·Status: COMPLETED ·Phase: PHASE3

Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule

NCT01499121 ·Status: COMPLETED ·Phase: PHASE2